Base Rate Fallacy and COVID-19 Testing - Considerations For Policy
Base Rate Fallacy and COVID-19 Testing - Considerations For Policy
Base Rate Fallacy and COVID-19 Testing - Considerations For Policy
page 1 of 3
i Director and Head of Analytics, Business Brio, Kolkata
ii Bayes’ Theorem. Although the formal probability statement is a textbook application of this famous theorem, the
informal sample proportion statement (like how it is stated here) can easily be derived from first principles by
elementary arithmetic; see vii below
iii This is a case of a type of bias in judgment that, some cognitive psychologists have argued, arises out of
insensitivity to prior probability of outcomes. Refer to page 1 of:
Judgment under Uncertainty: Heuristics and Biases
Author(s): Amos Tversky and Daniel Kahneman
Source: Science, New Series, Vol. 185, No. 4157, (Sep. 27, 1974), pp. 1124-1131
https://www.jstor.org/stable/1738360?origin=JSTOR-pdf
iv Accuracy may be misleading and so usually specificity and sensitivity are considered separately; here “high
accuracy” is meant as simultaneously high specificity and sensitivity. In this paper, for simplicity “99% accuracy”
denotes specificity = sensitivity = 99%, etc., though in reality specificity and sensitivity of a test are usually not the
same. For low prevalence, however, it is the specificity that is more influential on FDR, though
v To put this in the context of COVID-19, as of 21 May 2020, Qatar has among the highest case prevalence as a % of
the whole population at 1.34%; on that same date the rates for the US and India are 0.49% and 0.0086%
respectively [Source: https://www.worldometers.info/coronavirus/]
Test “Accuracy”
Prevalence 99.90% 99.00% 98.00%
Qatar 1.34% 6.90% 42.70% 60.04%
US 0.49% 16.90% 67.20% 80.6
India 0.0086% 92.10% 99.10% 99.60%
It should be noted that these quoted “case prevalence rates” are simply computed by dividing the number of
positive cases (usually from tests) with the country’s population and, the testing strategy and coverage vary among
countries and with time
vii
( 1−specificty )×( 1− prevalence )
FDR=
sensitivity× prevalence+ ( 1−specificty )×( 1− prevalence )
1
=
sensitivity prevalence
1+ ×
1− prevalence 1−specificity
1
=
sensitivity 1
1+ ×
1−specificity 1
−1
prevalence
The total cases that are identified as positive (the denominator in the first expression above) is the sum of two
components: a) those that are actually positive and correctly identified as such, and b) those that are actually
negative but erroneously identified as positive.
Low prevalence means that there are many more negative cases than positive ones in the population. Specificity is
the measure of how well the test can correctly identify the real negative cases. A test with slightly imperfect
specificity will have a small false positive rate (as a % of real negatives) but since the number of real negatives are
very high, this will still translate to a significant number of false positives.
Sensitivity, on the other hand, measures how well the test can correctly identify the real positive cases. Now,
because of low prevalence, the number of real positive cases will be small to begin with. This not only makes
component b) dominant over component a) and hence results in high FDR (by definition) but also makes the FDR
sensitive to small changes in the specificity, as the high number of real negatives accentuates the small false
positive rate. The fallacy becomes pronounced whenever the false positive rate is larger than the (low) prevalence
rate. Also, ibid iv, vi
viii Strictly speaking a test with perfect (= 100%) specificity irrespective of (even poor, but non-zero) sensitivity. It is,
however, not easy to empirically establish perfect specificity (to say nothing of the technical difficulties of
developing such a test in the first place): Even if 100 known disease free individuals are all correctly identified by
the test as negative then also the 95% confidence interval for the specificity is (96.4%, 100%)
For example of a real time RT-PCR for SARS-CoV-2 test specificity see
https://www.fda.gov/media/136231/download
x It is crucial to consider the prevalence rate in the sub-population that is being tested; If only symptomatic and/or
high-exposure-risk (e.g., medical providers or close contacts of otherwise confirmed cases) people are being tested
then the prevalence rate among them might be a lot higher than what would be the case if the general population are
being tested at random. Or, conversely, if the general population, regardless of symptoms and index of suspicion,
are being tested at random, then there will be much higher FDR; this can be a reasonable argument for not doing
general testing in the early stages of the pandemic